Artivion (NYSE:AORT) Insider John Davis Sells 2,075 Shares

Artivion, Inc. (NYSE:AORT) insider John Davis sold 2,075 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total value of $74,056.75. Following the transaction, the insider directly owned 188,868 shares of the company’s stock, valued at approximately $6,740,698.92. This trade represents a 1.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Artivion Stock Performance

NYSE:AORT traded up $0.31 during trading hours on Wednesday, reaching $35.66. The stock had a trading volume of 300,261 shares, compared to its average volume of 399,410. The stock has a market cap of $1.71 billion, a P/E ratio of 178.32 and a beta of 1.59. The stock has a 50 day simple moving average of $42.51 and a 200 day simple moving average of $43.14. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue was up 19.2% compared to the same quarter last year. On average, research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on AORT. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citizens Jmp raised their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Canaccord Genuity Group dropped their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.97.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after buying an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the period. Oppenheimer Asset Management Inc. purchased a new position in Artivion during the second quarter worth about $669,000. Finally, Envestnet Asset Management Inc. grew its position in Artivion by 364.4% during the second quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock worth $1,644,000 after buying an additional 41,487 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.